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Abstract
The conserved internal trimeric coiled-coil of the N-heptad repeat (N-HR) of HIV-1 gp41 is transiently exposed during the
fusion process by forming a pre-hairpin intermediate, thus representing an attractive target for the design of fusion
inhibitors and neutralizing antibodies. In previous studies we reported a series of broadly neutralizing mini-antibodies
derived from a synthetic naı ¨ve human combinatorial antibody library by panning against a mimetic of the trimeric N-HR
coiled coil, followed by affinity maturation using targeted diversification of the CDR-H2 loop. Here we report crystal
structures of the N-HR mimetic 5-Helix with two Fabs that represent the extremes of this series: Fab 8066 is broadly
neutralizing across a wide panel of B and C type HIV-1 viruses, whereas Fab 8062 is non-neutralizing. The crystal structures
reveal important differences in the conformations of the CDR-H2 loops in the complexes that propagate into other regions
of the antigen-antibody interface, and suggest that both neutralization properties and affinity for the target can be
attributed, at least in part, to the differences in the interactions of the CDR-H2 loops with the antigen. Furthermore,
modeling of the complex of an N-HR trimer with three Fabs suggests that the CDR-H2 loop may be involved in close
intermolecular contacts between neighboring antibody molecules, and that such contacts may hinder the formation of
complexes between the N-HR trimer and more than one antibody molecule depending on the conformation of the bound
CDR-H2 loop which is defined by its interactions with antigen. Comparison with the crystal structure of the complex of 5-
Helix with another neutralizing monoclonal antibody known as D5, derived using an entirely different antibody library and
panning procedure, reveals remarkable convergence in the optimal sequence and conformation of the CDR-H2 loop.
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Introduction
The initial steps of fusion of HIV-1 virus to host cells involve
binding of the HIV-1 surface envelope (Env) glycoprotein gp120 to
the primary receptor CD4 and the chemokine co-receptor
CXCR4 or CCR5 [1,2]. These binding events trigger a series of
conformational changes in both gp120 and the associated Env
glycoprotein gp41 that lead to the formation of a so-called pre-
hairpin intermediate (PHI) of the ectodomain of gp41 [3]. In the
PHI, the C-heptad repeat (C-HR; residues 623–663) and the
helical coiled-coil trimer of the N-heptad repeat (N-HR, residues
542–591) do not interact with one another, but rather bridge the
viral and target cell membranes. The C-terminal transmembrane
region of gp41 remains inserted into the viral membrane and the
N-terminal fusion peptide of gp41 is inserted into the target cell
membrane [3–5,2,6]. Subsequent apposition of the trimeric N-HR
coiled-coil with three C-HR’s results in the formation of a six-helix
bundle (6-HB) that brings the viral and cell membranes into close
proximity, eventually leading to their fusion [7–10]. The PHI
constitutes an attractive target site for fusion inhibitors since both
the N-HR and C-HR are accessible [11–31]. Moreover, the N-
HR is highly conserved across a wide range of HIV-1 strains, and
PLoS Pathogens | www.plospathogens.org 1 November 2010 | Volume 6 | Issue 11 | e1001182it has recently been shown that neutralizing antisera can be elicited
by vaccination with a disulfide stabilized, trimeric peptide mimetic
of the N-HR [32].
Recently, a number of monoclonal antibodies directed against
the N-HR of gp41, many of them shown to neutralize HIV-1 to
varying degrees, have been reported [33–40]. One such antibody,
D5 [34,41], was derived from a naı ¨ve human scFv library selected
by panning against an inner core mimetic of gp41, known as 5-
Helix. The 5-Helix construct comprises a single chain in which the
N-HR trimeric coiled-coil is surrounded by only two C-HR
helices, thereby exposing one face (comprising two N-HR helices)
of the internal trimeric N-HR coiled-coil [15]. A crystal structure
of D5 complexed to 5-Helix (PDB code 2CMR) reveals that one of
the predominant interactions involves the complementarity
determining region CDR-H2 loop of D5 protruding into the
conserved hydrophobic pocket of 5-Helix [41].
In previous studies [35,39] we reported a series of broadly
neutralizing mini-antibodies derived from a synthetic human
combinatorial antibody library (HuCAL GOLD [42]), comprising
more than 10
10 human specificities, by panning against the
chimeric gp41-derived construct NCCG-gp41 [16]. The latter
molecule exposes, in a stable manner, the complete N-HR internal
trimeric coiled coil in the form of a disulfide-linked trimer. The
parental Fab 3674 [35] was subjected to affinity maturation
against the NCCG-gp41 antigen using targeted diversification of the
CDR-H2 loop which resulted in significant enhancement of HIV-
1 neutralization properties, both in terms of IC50 and neutraliza-
tion breadth, over a standard panel of Envs from contemporary
primary isolates of HIV-1 subtypes B and C [39]. Indeed, the best
affinity-matured Fab in a monovalent format was comparable in
its neutralization potency to the parental Fab 3674 in a bivalent
format. The structural basis of such properties was, however, not
previously characterized. Here we report the crystal structures of
two affinity matured Fabs from this series (8066 and 8062), each
complexed to 5-Helix. These Fabs represent the extremes of this
series, since Fab 8066 was the most potent of the affinity matured
Fabs, whereas Fab 8062 did not exhibit any detectable
neutralization activity. The affinity of both Fabs for NCCG-gp41,
determined by solution equilibrium titration using an electro-
chemiluminescence-based affinity measurement, was comparable
(KD ,15 nM) [39], although the affinity of Fab 8066 for 5-Helix
measured by isothermal calorimetry (this work) is more than two
orders of magnitude higher than that of Fab 8062. The crystal
structures reveal important differences in the conformations of the
CDR-H2 loops of the Fabs in the two complexes that provide a
structural basis for the differences in neutralization properties and
affinity for 5-Helix of the two Fabs.
Results
Characterization of Fab 8062 and 8066 complexes with 5-
Helix
To assess complex formation between the Fabs and 5-Helix, we
carried out size exclusion chromatography with detection by
multi-angle light scattering and refractive index (SMR) (Fig.1).
Stable complex formation was demonstrated by the appearance of
a single peak that is retained with a mass of 7244061014 Da
(Fig. 1A, red). The peaks corresponding to Fab 8066 (Fig. 1A,
black) and 5-Helix (Fig 1A, red) have masses of 494806594 and
246806592, respectively. The calculated masses of Fab 8066 and
5-Helix are 48896 and 24459, respectively.
The affinity for 5-Helix of Fab 8066 and 8062, as well as the D5
antibody, was assessed by isothermal titration calorimetry (Fig. 1B
andTable1).ThestoichiometryofbindingdeterminedbyITCis1:1
for the complexes of the two Fabs (8066 and 8062) with 5-Helix, in
agreement with the SMR data. The D5 monoclonal antibody,
however,isa bivalentfull-length IgG,andhencethestoichiometryof
5-Helix to D5 is 2:1. The KD values for the binding of Fab 8066, D5
(Fab and IgG) and Fab 8062 to 5-Helix are ,,10 nM, 10–20 nM
and ,200 nM, respectively. For these three antibodies, the binding
data with 5-Helix correlate with neutralization activity. The HIV-1
neutralization potency of Fab 8066 (in monovalent format) is 1.5 to
4-fold higher than that of both the D5 IgG and Fab in an Env-
pseudotyped neutralization assay using Envs from four laboratory-
adapted strains of HIV-1 (HXB2, SF162 JR CSF, and 89.6). Fab
8062, on the other hand, displays no neutralization activity towards
these four strains (Table 1). It should also be noted that the bivalent
format of Fab 8066 is 2-7 fold more potent than the monovalent
format in terms of neutralization activity over a large panel of
subtype B and C HIV-1 strains [39].
Overall characteristics of the antibody-binding epitope
on 5-Helix
The crystal structures of Fab 8066 and 8062 complexed to 5-
Helix were determined at 2.05 and 2.5 A ˚ resolution, respectively
(Table 2). Representative electron density maps for the CDR-H2
loops of both complexes are shown in Fig. 2. The structures of
these two Fabs were compared to the previously published 2 A ˚
resolution crystal structure of a complex of the D5 antibody with
5-Helix [41]. The 5-Helix construct can be denoted as Na-L-Ca-L-
Nb-L-Cb-L-Nc, where Na, Nb and Nc are the three N-HR helices
that form the internal trimeric coiled-coil of gp41, Ca and Cb are
the first two C-HR helices of the 6-HB of gp41, and the L
segments are 5-residue linkers; the Cc helix of the 6-HB is absent in
5-Helix [15]. In the context of the 6-HB trimer, Na and Ca, Nb and
Cb, and Nc and Cc belong to three separate subunits. It should be
noted that identification of the helices is different here than in the
D5 complex, where the numbering of residues was incorrect by
not depicting the actual connectivity of helices in 5-Helix (for
details, see Figure S1 in Supporting Information S1). Since the
amino acid sequences are identical among the three N helices, as
well as in the two C helices, such a numbering change does not
affect the nature of the intermolecular interactions between the
Author Summary
Membrane fusion of HIV-1 with its target cells represents
the first step in viral infection. This process involves a series
of conformational changes in two viral envelope glyco-
proteins, gp120 and gp41, subsequent to binding of
gp120 to the CD4 receptor and the chemokine coreceptor
on the target cell membrane. During the fusion process,
the conserved N-heptad repeat (N-HR) of gp41 in the form
of a trimeric coiled-coil is accessible and presents an
attractive target for the generation of broadly neutralizing
antibodies. Here we present the crystal structures of two
monoclonal Fabs complexed to a mimetic of the N-HR
trimer. These Fabs were derived from a synthetic human
combinatorial antibody library comprising more than 10
10
human specificities by first panning against an N-HR
mimetic, followed by affinity maturation through targeted
diversification of the CDR-H2 complementarity determin-
ing region. One of the Fabs is broadly neutralizing across a
wide range of primary isolates from subtype B and C HIV-1,
whereas the other one is non-neutralizing. Our structures
reveal the key role of the CDR-H2 loop in antigen
recognition and how this correlates with HIV-1 neutraliza-
tion properties.
Complexes between Fabs and gp41-Derived 5-Helix
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helices does change the assignment of intra- and intersubunit
interactions when interpreted in the context of the 6-HB trimer.
The overlapping epitope, which is recognized by both Fabs on
the surface of 5-Helix (Fig. 3A), is similar to the one described in the
structure of the D5/5-Helix complex. This epitope comprises three
helices, Na, Nc and Ca, out of the five present in 5-Helix (Figs. 2B,C).
The Na helix is located in the middle of the epitope and thus
contributes residues to the interactions with five CDRs of the
antibodies. Two CDRs, H1 and H2, interact with residues in the
groove located between helices Nc and Na, while the other two
CDRs, H3 and L3, interact with residues in the groove located
between helices Na and Ca. CDR-H2 covers the groove between Na
and Nc and is positioned primarily over the Na helix (Figs. 3B,C).
The total accessible surface area buried at the antigen/antibody
interface is comparable for the Fab 8066 and 8062 complexes with
5-Helix (,2300 A ˚ 2) and divided approximately equally between
antigen and antibody. This area is ,250 A ˚ 2 greater than for the
D5/5-Helix complex. The interactions with the heavy chain
CDRs bury about twice as much accessible surface as those with
the light chain CDR’s. The number of residues at the interface
(defined as residues whose accessible surface area decreases by
.1A ˚ 2 upon complexation [43]) is also similar for the Fab 8066
and 8062 complexes (,60 residues subdivided equally between
antibody and antigen) and somewhat larger than for the D5
complex (53 residues, 28 from the antibody and 25 from 5-Helix).
Despite the overall similarity of the three antibody or Fab
complexes with 5-Helix, there are significant differences in the
conformations of the corresponding CDRs, as well as in the
conformation of the interacting residues within the antibody-
antigen interface. These differences are strongly correlated with
the variations in the sequences of the CDRs. The amino acid
sequences of all CDRs other than CDR-H2 differ markedly
between D5 and Fab 8066, leading to obvious structural
differences in these segments. Fortuitously, the CDR-H2 of Fab
8066 and D5 converged to highly homologous sequences in the
selection procedures used to generate these antibodies (Fig. 3E),
leading to similarities in the conformation of this part of their
structures. By way of contrast, the CDR-H2 sequences of Fabs 8066
and 8062 diverged during affinity maturation (Fig. 3E), resulting in
significant differences in their conformations. These conformational
differences, as well as the altered interaction patterns, may be
reflectedindifferentbiologicalpropertiesofthesethreeantibodies,as
manifested by the binding and neutralization data shown in Table 1.
The conformations of CDRs H1, H3, and L3 of Fabs 8066 and
8062 in the complexes with 5-Helix and their interactions with the
antigen are most similar. CDRs H3 and L3 interact with residues
from Na and Ca helices, and therefore are positioned in a shallow
groove between these two helices on the surface of 6-HB (Fig. 3B).
Detailed analysis of the interactions between the CDRs and the
antigen (Table S1 in Supporting Information S1) indicates that,
prior to affinity maturation of CDR-H2, CDR-L3 and CDR-H3
carried most of the interface interactions. The loops in both CDR-
L3 and CRD-H3 are shorter in the D5 antibody (by 2 residues
Table 1. Thermodynamics of 5-Helix binding and HIV-1
neutralization activity.
Antibody
Binding
to 5-
Helix HIV-1 neutralization IC50 (nM)
b
KD (nM)
a HXB2 SF162 JR CSF 89.6
Fab 8066 ,,10 85675 5 0 680 490650 550670
Fab 8062 ,200 NA
c NA
c NA
c NA
c
Fab D5 ,10 300640 13006300 6406140 8906200
IgG D5 ,20 230640 9406160 640680 22406350
aITC measurements were carried out at 28uC in 10 mM Tris buffer, pH 7.5,
150 mM NaCl.
bHIV-1 neutralization activity was measured using an Env-pseudotyped virus
neutralization assay as described previously [39] with Envs from four HIV-1
subtype B laboratory-adapted strains, HXB2, SF162, JR CSF and 89.6. Fabs 8066
and 8062 are in monovalent format.
cNA, no activity. Neutralization was too weak to reliably determine an IC50.
doi:10.1371/journal.ppat.1001182.t001
Figure 1. Characterization of the interaction of Fab 8066, Fab 8062 and the D5 antibody with 5-Helix. (A) Molecular mass analysis of 5-
Helix (blue), Fab 8066 (black) and a mixture of Fab 8066 and 5-Helix in a 1:2 molar ratio (red) by analytical size-exclusion chromatography with inline
multiangle light scattering and refractive index measurements (SMR). Measured average masses are 7244061014 Da for the Fab 8066/5-Helix complex,
494806594 Da for Fab 8066 (calculated 48,896 Da) and 246806592 Da for 5-Helix (calculated 24,459 Da). (B) ITC measurements for the binding of Fab
8066 (top), Fab 8062 (middle) and the D5 antibody (bottom) to 5-Helix in 10 mM Tris buffer, pH 7.5, 150 mM NaCl at 28uC. Thermal changes were
monitored on addition of 2.45-ml aliquots of 100–150 mM 5-Helix solution to 5–15 mM Fab/antibody in the calorimetric cell (volume 0.2049 ml). Binding
constantsandthermodynamic parameters obtainedby curve fitting of the integrated data to a simplesingle site binding model areprovided in Table 1.
doi:10.1371/journal.ppat.1001182.g001
Table 2. Crystallographic data collection and refinement
statistics.
Fab 8066/5-Helix Fab 8062/5-Helix
Data collection
Wavelength (A ˚) 1.000 1.000
Space group P212121 P21
Unit cell parameters (A ˚) a=41.5, b=124.7,
c=133.7
a=83.7, b=41.7,
c=98.6
b=94.85u
Resolution (A ˚) 50.0–2.04 50.0–2.5
Number of reflections
(unique/total)
44,497 (213,954) 23,655 (73,516)
Completeness (last shell) 99.2% (96.6%) 99.1% (96.7%)
Rmerge 9.9% (66.2%) 8.2% (52.4%)
Refinement
No. of complexes in a.u. 1 1
No. of protein atoms 4794 4805
No. of solvent molecules 443 69
No. of heteroatoms 2 0
Rcryst 19.3% 20.0%
Rfree (3%) 24.5% 26.4%
r.m.s. deviation from ideality
Bond lengths (A ˚) 0.010 0.010
Bond angles (u) 1.21 1.19
Ramachandran
most favored (%) 94.4 92.4
additionally allowed (%) 5.6 7.6
PDB ID 3MA9 3MAC
doi:10.1371/journal.ppat.1001182.t002
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PLoS Pathogens | www.plospathogens.org 4 November 2010 | Volume 6 | Issue 11 | e1001182Figure 2. Representative 2Fo-Fc electron density maps. CDR-H2 loop (residues 51–59) in (A) the Fab 8066/5-Helix complex and (B) the Fab
8062/5-Helix complex contoured at 1.5 and 1.0 s, respectively.
doi:10.1371/journal.ppat.1001182.g002
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the antibody, as well as for the reduced number of the antigen-
antibody interactions in the D5 complex, compared to the two Fab
complexes. The effect of the differences in length of CDR-L3 and
CDR-H3 is illustrated in Fig. 3D, where all three complexes are
superimposed based on the Ca coordinates of the antibodies.
Comparative analysis of the individual CDRs in the three
complexes
The conformation adopted by CDR-H1 in the complexes of
Fabs 8066 and 8062 with 5-Helix is very similar. Two residues of
CDR-H1, Ser-31 and Ala-33, interact with His-23 and Leu-27 of
helix Na of 5-Helix, and their mode of interactions is essentially the
same in both complexes (Fig. 4) (Italics are used throughout for
residues of 5-Helix.) Although the side chain of Ser-31 is found in
two orientations in the Fab 8066 complex, compared to a single
conformation in the Fab 8062 complex, a long hydrogen bond
between its carbonyl oxygen and the Ne2 atom of His-23 is present
in both complexes. The other contacts involving CDR-H1 are
hydrophobic. When compared to the D5 complex, an additional
hydrophobic contact is made between Ala-33 and Trp-30, due to
the different orientation of the latter’s side chain (Fig. 4 and Table
S1 in Supporting Information S1).
Figure 3. Overall view of the Fab/5-Helix complexes. (A) Interaction of all the CDRs with 5-Helix in the Fab 8066 and Fab 8062 complexes. The
CDRs are shown as stick models with the carbon atoms in green for Fab 8066 and in orange for Fab 8062. 5-Helix is shown as a ribbon with the N-
helices in cyan and the C-helices in dark blue. A transparent molecular surface of 5-Helix is also shown with the accessible surfaces of positively and
negatively charged residues depicted in blue and red, respectively. (B-D) Superposition of the backbone of the Fab 8066, Fab 8062, and D5
complexes with 5-Helix, displayed as green, yellow and cyan tubes, respectively, superimposed on the Ca atoms of 5-Helix in (B) and (C) and on the
Ca atoms of the antibodies in (D). (E) Comparison of the CDR-H2 sequence of the parental Fab 3674 with that of Fabs 8066 and 8062, as well as the
D5 antibody [34]. The residue numbering of the CDR-H2 is according to [51].
doi:10.1371/journal.ppat.1001182.g003
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in a groove between helices Nc and Na of 5-Helix (Fig. 3C). CDR-
H2 in the antibody/5-Helix complexes effectively substitutes for
the N-terminal end of the Cc helix that is present in the six-helix
bundle of complete gp41, but is absent in 5-Helix. The significance
of the interactions made by CDR-H2 residues might be attributed
to the unique orientation of this loop, which lies parallel to the
surface of the epitope and covers the groove like a lid (Fig. 3C).
This mode of interaction distinguishes CDR-H2 from the other
CDRs which are all oriented approximately perpendicular to the
interface. Because of the unique position of CDR-H2, every
residue of this loop is involved in the interactions with the antigen.
The amino acid sequence of the CDR-H2 loop converged during
selection to be almost identical in Fab 8066 and the D5 antibody,
with the exception of a single residue (Thr-57 in Fab 8066 is an
Ala in D5), and therefore the interactions of CDR-H2 with
5-Helix are very similar in both complexes (Fig. 5A). The
interactions involving CDR-H2 are predominantly hydrophobic,
and the few polar interactions that are present vary between the
two complexes (Table S1 in Supporting Information S1). Two
such polar interactions are unique to the Fab 8066 complex, and
involve a short hydrogen bond between the side chains of Thr-57
of CDR-H2 and Arg-38 of the Na helix, as well as a hydrogen bond
between the side chains of Asn-58 and Gln-34 (Fig. 5A). In the D5
complex, Asn-58 is forced to adopt a different conformation due to
the close proximity of the bulky side chain of Tyr-94 of CDR-L3.
The structural equivalent of the latter residue in Fab 8066 is the
much smaller Val-95 (Fig. 5A).
In the case of Fabs 8066 and 8062, the sequence of CDR-H2
diverged during affinity maturation (Fig. 3E), leading to a different
conformation of this loop, as well as to variations of the interaction
pattern in the two complexes (Fig. 5B). Nevertheless, a majority of
the hydrophobic interactions are preserved for those residues of
CDR-H2 that are either identical or of a similar type (for example,
Ile/Leu-53) in both Fabs. Some of the polar interactions in the Fab
8062 complex are lost, and compensated by additional hydro-
phobic interactions (Table S1 in Supporting Information S1). For
example, a hydrogen bond between Asn-58 of CDR-H2 and Gln-
34 of the Na helix, present in the Fab 8066 complex, is substituted
by hydrophobic interactions between the side chain of Val-58 of
Fab 8062 and the same residue of 5-Helix (Gln-34). However, the
hydrogen bond between Thr-57 of CDR-H2 and Arg-38 of the Na
helix in the Fab 8066 complex has no equivalent in the Fab 8062
complex due to the Thr-57Ala substitution in the latter. A
hydrogen bond between the carbonyl oxygen of Thr/Ala-57 and
the side chain of Arg-38 is present in both complexes (Fig. 5B). A
hydrogen bond formed between the side chains of Thr-56 and
Gln-34 of the Na helix in Fab 8066 complex is not found in the Fab
8062 complex, since the latter has a Phe in the corresponding
position. In turn, the large Phe side chain is involved in extensive
hydrophobic interactions between Fab 8062 and 5-Helix. As a
result, the number of contacts between the two Fabs and 5-Helix is
comparable. Nevertheless, when the topography of the CDR-H2
loops within two Fab complexes is reviewed, a significant
difference can be noticed (Fig. 5C). Substitution of Thr-56 in
Fab 8066 by Phe-56 in Fab-8062 results in shifting of the whole
segment of the CDR-H2 loop out of the groove on the surface of
the bundle, where it was docked in the Fab 8066 complex. Thus,
while the hydrophobic interactions between Phe-56 and 5-Helix
are preserved, including an unfavorably short one (3.2 A ˚) with
Gln-212 of the Nc helix, this substitution results in displacement of
the main chain surrounding Phe-56 away from 5-Helix.
The CDR-H3 sequences are identical in Fabs 8066 and 8062,
and these loops maintain very similar conformations in the
complexes with 5-Helix. As noted above, residues of CDR-H3
interact with the residues in the groove between the Na and Ca
helices of 5-Helix, maintaining very similar contacts, with only a
slight variation in the distances between the same pairs of atoms
(Fig. 6). The interactions are predominantly of a hydrophobic
nature, with only a few polar interactions. One strong hydrogen
bond between the hydroxyl of Tyr-102 and His-65 (2.7 A ˚) in the
Fab 8066 complex is lost in the Fab 8062 complex, due to different
orientation of the side chain of His-65 in the two complexes. His-
65 has two alternate conformations in the Fab-8066 complex, but
only a single one in the Fab 8062 complex, most likely due to the
differences in the conformation of CDR-L1 in the two complexes.
The hydrogen bond between Tyr-102 and His-65 in the Fab 8066
complex is formed with the histidine side chain adopting the
conformation that is absent in the Fab 8062 complex.
The number of contacts involving interactions of CDR-L1 and
CDR-L2 with 5-Helix is much lower than for the other CDRs
discussed above. The conformation of CDR-L1 is different in each
of the three antibody complexes compared here. However, as the
CDR-L1 sequences are identical in Fabs 8066 and 8062, their
interactions with 5-Helix are similar, with differences attributed to
crystal contacts present in the Fab 8066 complex (Fig. 7A). CDR-
L1 maintains the interactions on the periphery of the epitope,
mostly with residues from helix Ca (Fig. 3B). Only two residues
with bulky side chains, Trp-30 and Lys-33 from helix Na, extend to
CRD-L1 and interact with the side chain of Tyr-31, and these
intermolecular contacts are shorter in the Fab 8066 complex
(Fig. 7A). The side chains of Glu-30 adopt different conformations
in the two complexes. In the Fab 8066 complex Glu-30 is
hydrogen bonded to Ser-62, whereas in the Fab 8062 complex this
residue forms an ion pair with His-65. One additional hydropho-
bic interaction in the Fab 8066 complex that is not present in the
Fab 8062 complex is found between Pro-28 and the Cc atom of
Asn-58; in the Fab 8062 complex Pro-28 is oriented away from the
bundle. Although CDR-L1 in the D5 complex recognizes the
same part of the 5-Helix epitope as the corresponding CDRs in the
other two complexes, its conformation differs from both of them.
Figure 4. Comparison of the interactions of CDR-H1 of Fabs
8066 and 8062 with 5-Helix. The color coding is as follows: side
chains of Fab 8066 and 8062, green and orange carbon atoms; side
chains of 5-Helix in the Fab 8066 and 8062 complexes, cyan and yellow,
respectively. The position of Trp-30 of 5-Helix in the D5 complex [41] is
shown in pink. A transparent molecular surface of 5-Helix is displayed
with the accessible surfaces of positively and negatively charged
residues colored in blue and red, respectively.
doi:10.1371/journal.ppat.1001182.g004
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PLoS Pathogens | www.plospathogens.org 8 November 2010 | Volume 6 | Issue 11 | e1001182Such different conformation of CDR-L1 in the D5 complex is due
not only to the unique sequence of this loop, but also to the
presence in the interface of a glycerol molecule from the
cryoprotectant (Fig. 7B), which mediates antigen-antibody inter-
actions [41].
The conformation of CDR-L2 is similar in all three complexes,
except that in the Fab 8066 complex the tip of the CDR-L2 loop is
oriented more towards 5-Helix then in the other two complexes.
This allows formation of two solvent-mediated interactions with
His-65 and Glu-69 of helix Ca (Fig. 8). In the Fab 8062 complex,
CDR-L2 is not involved in any contacts with the antigen.
The conformation of CDR-L3 is very similar in the Fab 8066
and 8062 complexes. The tip of this loop is oriented into the
groove between helices Na and Ca (Fig. 8). In the Fab 8066
complex, two residues on the tip of CDR-L3, Ser-92 and Met-93,
interact with two residues from the helix Ca, Met-51 and Asn-58,
respectively. No equivalent interactions are seen in the Fab 8062
complex, but several other hydrophobic contacts are similar in
both complexes.
Binding of CDR-H2 and CDR-H1 prevents the completion
of the six-helix bundle
When the first 6-HB structures of the gp41 ectodomain emerged
[7–10], key hydrophobic interactions between residues located on
the N-terminus of a C-HR helix, and the C-termini of two
adjacent N-HR helices in the trimer, were described. Several
residues, such as Trp-628, Trp-631 and Ile-635 on the C-HR helix
and Ile-573 and Val-570 (Ile-208 and Val-205 in the Fab 8066 and
8062 complexes, respectively) on the N-HR helix from the same
molecule of gp41, maintain numerous intramolecular hydrophobic
interactions (numbering for the Cc residues is taken from the 1AIK
structure [7] and corresponds to the numbering of the native
gp160 sequence). These interactions were identified to play a
crucial role for the stability of the 6-HB and hence for successful
initiation and completion of the fusion process [7–10].
When complexed to 5-Helix, the CDR-H2 and CDR-H1 of
Fabs 8066 and 8062, as well as D5, occupy the space taken by
N-terminal end of the C-HR helix (Cc) in the 6-HB structure.
Indeed, the segment of the CDR-H2 in Fab 8066 comprising
residues 51–58 literally takes the place of the position of the N-
terminus of the third C-HR helix in the gp41 trimer. In particular,
the side chains of Phe-54, Ile-53 and Thr-56 of CDR-H2 preserve
the interactions with Ile-208 and Val-205 of the Nc helix,
substituting for the intrasubunit interactions between the Nc and
Cc helices of the 6-HB (Fig. 9A). Interestingly, the conformations of
the hydrophobic residues on the Nc and Na helices are not
significantly affected by the binding of the antibody, and the
topography of the surface between the two adjacent N-HR helices,
Nc and Na, required for successful docking of the Cc helix seems to
be unperturbed with only two exceptions, namely the side chains
of His-23 and Trp-30 (His-564 and Trp-571 in gp41).
In the case of His-23, both the x1 and x2 angles adopt different
rotamers, with the result that the hydrogen bond between the Nd
atom of His-23 of the Na helix and the hydroxyl of Tyr-638 of the
Cc helix in the 6-HB is replaced by a hydrogen bond between the
Ne atom of His-23 and the carbonyl of Ser-31 of CDR-H1 in the
Fab 8066/5-Helix complex (Fig. 9A). Likewise, the side chain of
Trp-30 in the Fab/antibody complexes with 5-Helix also changes
its conformation relative to that found in the 6-HB: for the Fab
8066 and 8062 complexes there is a ,180u flip in the x2 angle,
while for the D5 complex both the x1 and x2 rotamers are altered.
In the absence of Fab/antibody the intersubunit hydrophobic
interactions between Trp-30 of Na (Trp-571 of a N-HR helix of
gp41) and two tryptophans (Trp-628 and Trp-631) of a C-HR helix
are strictly conserved within all 6-HB and 5-Helix structures solved
to date (Fig. 9B). (In 5-Helix these interactions occur between
helices Nb and Ca and between Nc and Cb). It seems reasonable to
suggest that the formation of such an intersubunit ‘‘tryptophan
lock’’ serves to optimally align the hydrophobic moieties on a
given C-HR helix and two adjacent N-HR helices to form a
hydrophobic zipper along the axis of the bundle. In the context of
HIV-1 neutralization, binding of Fabs 8066 and 8062 and the D5
antibody compete with the formation of the intersubunit
‘‘tryptophan lock’’. Hence, even subtle differences in the stability
of the complexes with various antibodies under conditions of
ongoing competition can determine the success in blocking
productive 6-Helix bundle formation vital for viral fusion.
Modeling the complexes of the gp41 N-HR trimer with
FAbs 8066 and 8062
The crystal structures of the Fab complexes with 5-Helix
presented here involve a single antibody molecule substituting for
one C-HR helix. Apposition of the viral and target membranes
requires the conversion of the PHP in which the N-HR trimer is
exposed to a 6-HB in which the C-HR helices are bound to the
outside of the N-HR trimer. Success in the competition between
Figure 5. Stereoviews showing the interactions of CDR-H2 of Fab 8066, Fab 8062 and D5 with 5-Helix. (A) The Fab 8066 complex versus
the D5 complex [41]. (B) and (C) The Fab 8066 complex versus the Fab 8062 complex. Color coding: the carbon atoms of side chains of Fab 8066, Fab
8062 and D5 are shown in green, orange and magenta, respectively; the carbon atoms of side chains of 5-Helix in these three complexes are shown in
cyan, yellow and pink, respectively. Helices of 5-Helix are shown as ribbons with the N-helices in cyan and the C-helices in dark blue. A transparent
molecular surface of 5-Helix is included in (C), colored in purple for the Fab 8066 complex and in yellow for the Fab 8062 complex.
doi:10.1371/journal.ppat.1001182.g005
Figure 6. Comparison of the interactions of CDR-H3 of Fab
8066 and Fab 8062 with 5-Helix. Color coding: the carbon atoms of
side chains of Fab 8066 and Fab 8062 are shown in green and orange,
respectively. Only side chains of 5-Helix in the Fab 8066 complex are
shown with carbon atoms in cyan (as they are essentially identical in the
Fab 8062 complex). The Na and Ca helices of 5-Helix are shown as cyan
and dark blue ribbons. A transparent molecular surface of 5-Helix is also
included with the accessible surface of positively and negatively
charged residues in blue and red, respectively.
doi:10.1371/journal.ppat.1001182.g006
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of the PHP may depend on the ability of the antibody to form a
complex with more than one antibody molecule bound. In
principle, up to three antibodies could bind to three equivalent
sites on the N-HR trimer. Indeed, maximum antagonism between
Fab 8066 and the N-HR trimer mimetic NCCG-gp41 in the HIV-1
neutralization assay is observed at a molar ratio of 3:1 [39]: at this
ratio the concentrations of free NCCG-gp41 (which has 3 Fab
binding sites) available to bind the C-HR of gp41 and free Fab 8066
available to bind the N-HR trimer of gp41 are at a minimum. To
evaluate the impact of the observed structural differences in the
interactions of the CDR-H29s of the different Fabs with 5-Helix, we
modeled complexes of the three Fabs bound to a N-HR trimer.
Modeling is complicated by the fact that whereas the gp41
trimer is formed from three identical N-HR helices, only two of
the three N-HR helices, Na and Nc, interact with the Fab in the
Figure 7. Comparisons of the interactions of CDR-L1 of Fab 8066, Fab 8062 and D5 with 5-Helix. (A) The Fab 8066 complex versus the
Fab 8062 complex. (B) The Fab 8066 complex versus the D5 complex [41]. Color coding: the carbon atoms of side chains of Fab 8066, Fab 8062 and
D5 are shown in green, orange and magenta, respectively; the carbon atoms of side chains of 5-Helix in the Fab 8066, Fab 8062 and D5 complexes are
shown in cyan, yellow and pink, respectively, for the Na helix, and in blue, yellow and pink, respectively, for the Ca helix. The N- and C-helices of
5-Helix are shown as cyan and blue ribbons, respectively. The glycerol molecule (labeled GOL) in the D5 complex is shown in orange in (B).
doi:10.1371/journal.ppat.1001182.g007
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symmetry of the N-HR trimer is broken in the crystal structures.
To generate models of the N-HR trimer with three Fabs we used
as reference structures two coordinate sets comprising three N-HR
helices (Na, Nb, and Nc) and the Fab, which were extracted from
the two crystal structures of 5-Helix bound to single Fab molecule,
8066 or 8062. The fragment of the each reference structure,
containing helices Na and Nc, that interact with the Fab in the 5-
Helix complex, plus the Fab molecule itself, was treated as a rigid
body unit to create a model of a trimer with three Fabs bound.
We initially modeled the binding of two additional Fab
molecules by superimposing two N-HR helices of the rigid body
unit (Na and Nc) with two other helices of the trimer (first, with Nc
and Nb, and, subsequently with Nb and Na). The aim of this
approach was to preserve the intrinsic structure of the experi-
mentally observed gp41 trimer. The results are shown in Fig. 10.
The two modeled Fab 8066 molecules are reasonably well
positioned in a pseudo-symmetric fashion between pairs of N-
HR helices in the trimer, while two areas of steric clashes are
observed for Fab 8062. The first involves slightly short contacts
between CDR-L3 of one Fab and the CDR-H2 of another (2.2 A ˚
between the side chain of Met-93 and the carbonyl oxygen of Phe-
54, respectively). The second area displays short contacts for the
interactions between CDR-H2 and helix Nb of the trimer (1.7 A ˚
between the side chains of CDR-H2 Phe-54 and Gln-124 of Nb).
A closer look at the results of the modeling based on the
superposition of two pairs of helices explains the latter as follows.
The three N-HR helices are involved in very different types of
interactions in the 5-Helix complexes. The Nb helix interacts solely
with C-HR helices on both sides, while the Na and Nc helices each
interact on one side with a C-HR helix and on the other side with
a Fab molecule. When the Na and Nc helices of the rigid body unit
are superimposed on two other pairs of helices from a trimer, a
shift in the resulting positions of that pair of helices is observed in
the modeled structure, compared to their position in the original
structure of the 5-Helix complex. This shift originates from the
changes in the environment of each helix in the model, since all
three N-HR helices are involved in a similar type of interactions
with two Fabs on both sides. However, since helix Nb was used
twice during model building to create two Fabs on either side of it,
it has two distinct positions in the modeled structure, as can be
clearly seen in Fig.10, panel Nb. Thus, to accommodate a Fab on
the left side of helix Nb, helix Nb has to move to the right compared
to its position in the gp41 trimer, and vice versa. The ambiguity of
the positioning of helix Nb in the model demonstrates the
shortcomings of this approach. We conclude that to build a
model with three Fabs we should not constrain the structure of the
helical trimer. Nevertheless, results of such modeling consistently
indicate that the shifts in all three helices are larger when bound to
Fab 8062 than to Fab 8066, suggesting that that formation of the
complex with three Fab 8062 molecules requires more extensive
structural rearrangements.
To address problems with the first model, we used an alternative
approach in which only one helix out of two comprising the rigid
body unit is used for sequential superpositions. In this manner, the
second helix will be placed where it falls, and for the next round its
new position will be used in the superposition for the purpose of
creating the second modeled Fab. We fully realize the imperfec-
tions of such an approach, which will allow the trimer structure to
relax without any restrictions applied. The advantage, however, is
that the positions of each pair of helices is consistent with the
presence of the Fab molecule bound between them. The resulting
models are then only used for comparisons, although they are not
considered to be accurate in absolute terms.
Figure 8. Comparison of the interactions of CDR-L2 of Fab 8066 and Fab 8062 with 5-Helix. Color coding: the carbon atoms of side chains
of Fab 8066 and Fab 8062 are shown in green and orange, respectively; the carbon atoms of side chains of the Na and Ca helices in the Fab 8066
complex are in cyan and blue, respectively; the carbon atoms of the side chains of the Na and Ca helices in the Fab 8062 complex are in yellow. The
Na and Ca helices of 5-Helix are shown as cyan and dark blue ribbons. A transparent molecular surface of 5-Helix is also included with the accessible
surface of positively and negatively charged residues in blue and red, respectively.
doi:10.1371/journal.ppat.1001182.g008
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(Fab)3 complexes with Fabs 8066, 8062, and D5. Since we started
to build the models for each Fab from the superimposed crystal
structures, for clarity they are not shown. Similarly to the first
model, the shift in the position of the third Fab is most pronounced
for Fab 8062, less so for D5, and least for Fab 8066. This reflects
the extent of rearrangements in the trimer upon increasing the
ratio of Fabs to gp41 in the complexes. This is also confirmed by
comparing the shifts of the helices for individual Fab complexes
between the original and modeled structures (Fig. 11 G, H, I). The
Figure 9. Comparison of 5-helix complexed to Fab 8066 with the 6-HB structure of gp41. (A) The 5-Helix bundle from the complex with
Fab 8066 is superimposed onto the 6-HB trimer (both shown in cartoon representation, with the N-HR and C-HR helices in the Fab 8066 complex
colored cyan and dark blue, respectively, and in white for 6-HB). Hydrophobic residues in contact within the interface between the third C-HR helix
(denoted as Cc) that is absent in 5-Helix and the two adjacent N-HR helices (Na and Nc) are shown in sticks in the same color scheme as the cartoons.
Selected side chains are labeled, with letters a-d denoting Ile-53 of the Fab CDR-H2, Val-205 of helix Nc (V570 in the 6-HB), Leu-27 of helix Na (L568 in
the 6-HB), and Leu-24 of helix Na (L565 in the 6-HB), respectively. The side chain of Trp-30 in the D5 complex is in pink. The interactions within the 6-
HB are shown as black dashed lines. The CDRs H2 and H1 are shown as sticks, in dark and light green, respectively. The hydrogen bond between the
carbonyl of Ser-31 of the CDR-H1 and the imidazole ring of His-23 in the Fab 8066 complex is marked by a red dashed line. (B) Structures of the
intersubunit ‘‘tryptophan lock’’ in the 6-HB and 5-Helix. Nine pairs of interacting N-HR and C-HR helices from different molecules of gp41 are
superimposed. Three sets of tryptophan side chains seen in 6-HB gp41 trimers, two X-ray structure, pdb codes 1AIK [7] and 1ENV [8], and one NMR
structure, pdb code 1QCE [10,52], are shown in white, blue and red sticks, respectively. Three complexes of 5-Helix with antibodies provide six
independently determined structures of the ‘‘tryptophan lock’’. Two sets of tryptophan residues from the complexes with Fabs 8066 and 8062, and
the D5 antibody are shown in two shades of light green, yellow, and pink, respectively. The side chains of Trp-30 from the first N-HR helix (Na) in the
three complexes, which are involved in interactions with the CDR-H2 of the antibodies, as opposed to the third C-HR helix (Cc) which is absent in 5-
Helix, are shown in dark green, orange and magenta, respectively. N-HR and C-HR helices are shown in cartoon representation with the molecular
surface colored in light cyan and blue, respectively.
doi:10.1371/journal.ppat.1001182.g009
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areas with steric clashes at the interface between neighboring Fabs
(Fig. 11B). The first area of steric clash involves the CDR-H2 of
one Fab and the CDR-L3 of another (Fig. 11C), and the second
clash area involves loop 71-77 of one Fab and the CDR-L1 of the
other (Fig. 11D). Close contacts are only observed in the first area
for Fab 8062 (between Gly-55 and Met-93, Fig 11C), whereas no
bad intermolecular contacts are present for Fab 8066, owing to the
different conformation of the CDR-H2. Since CRD-L3 is shorter
in D5 than in the two others Fabs, it is also not involved in any
collisions. Interestingly, comparison with the neutralizing antibod-
ies DN9 (from a human B-cell library from an HIV infected
patient, selected using the engineered disulfide stabilized N-HR
trimer, N35CCG-N13), and 8K8 (raised in rabbits using N35CCG-
N13) reveals a high level of sequence similarity of their CDR-H29s
with that of Fab 8066 [38]. In DN9, a residue with a longer side
chain (Glu) occupies the position of Gly-55 (Table S2 in
Supporting Information S1), but position 56 is occupied, as in
Fab 8066, by Thr, which should allow avoidance of the collision
described above. In contrast, position 56 in 8K8 is occupied by a
long Arg side chain, but position 55 is still a Gly.
In the second area, short contacts are present in the trimer
models of both Fab 8062 and D5, involving Ser-74 in both, as well
as Asp-25 and Glu-27 of CDR-L1 in Fab 8062 and D5,
respectively (Fig. 11D). The contacts between the neighboring
Fabs in the model of the N-HR trimer-(Fab 8066)3 complex seem
to be much better. There are no bad contacts between the Fabs
and the individual helices in the N-HR trimer of the second
model, because the positions of the helices were shifting as the
model was being built to accommodate the Fabs.
Discussion
Although Fab 8066 and the D5 monoclonal antibody were
developed using completely different naı ¨ve antibody libraries with
different panning and selection procedures [34,35,39], the
interactions between their CDR-H2 loops and the hydrophobic
pocket of 5-Helix converged to similar solutions (Figs. 2E and 5A).
Affinity maturation of the CDR-H2 conveyed significant im-
provements in neutralization breadth and potency of Fab 8066
relative to its parental Fab 3674 [39], indicating that interactions
with this region of gp41 are crucial for efficient neutralization of
HIV-1.
Examination of the CDR-H2 sequences of a series of 10 affinity
matured Fabs generated from the parental Fab 3674 [39], as well
as the CDR-H2 sequences of D5 [41], DN9 and 8K8 [38] reveal
that the key determinants relating to neutralization activity are
correlated with the nature of the residues at positions 53, 54 and
Figure 10. Superimposed models of the complexes of the trimer of N-HR helices of gp41 with three Fab molecules, built by
sequentially superimposing two pairs of helices. The overall view of the models is shown in a cartoon representation. The crystal structures of
the Fab complexes are colored cyan for Fab 8066 and yellow for Fab 8062, and the two modeled structures are colored navy blue and orange,
respectively. The panels marked Na, Nb and Nc show the shifts between the experimental and modeled positions of the N-HR helices, using the same
coloring scheme. Panel Nb shows two sets of helices in navy blue and orange, corresponding to their positions in the complexes with the Fabs
positioned on each side of helix Nb.
doi:10.1371/journal.ppat.1001182.g010
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neutralizing (Fabs 8060, 8066 and 8068), 3 Fabs (8059, 8064 and
8069) as well as the parental Fab (3674) displayed weak
neutralizing activity, and 4 Fabs (8061, 8062, 8063 and 8065)
had no detectable neutralization activity. The neutralizing Fabs
were all characterized by a Leu or Ile at position 53 with the
exception of Fab 8064 which had a Trp; a Phe at position 54; and
a polar residue at position 56. The presence of some of these key
residues in CDR-H2 sequences, when reviewed in the framework
of structural and modeling data presented in this study, seem to
correlate with their affinity and biological activity, as shown by a
few examples below.
Fabs 8064 and 8065 are of interest since they display very
different biological activity (neutralizing versus non-neutralizing,
respectively), their affinities for 5-Helix differ by a factor of ,30
(KD ,5–10 nM versus ,200 nM; unpublished data), and their
CDR-H2 sequences differ at only two positions (Phe versus His at
position 54, and Ser versus Gly at position 56). Both Fabs 8064
and 8065 have a bulky Trp at position 53 which likely necessitates
some conformational changes, probably propagating to CDR-H1
and CDR-L1, to circumvent steric clash (Fig. 12A). However, the
presence of a His at position 53 in Fab 8065 creates an
unfavorable environment by introducing a polar residue into a
hydrophobic pocket formed by Leu-27 and Thr-28 of helix Na and
Val-205 and Ile-208 of helix Nc.
Fab 8069 also exhibits some unusual features since it differs
from Fab 8062 by a single residue with a larger Trp substituting
for a Phe at position 56. The presence of the bulky Phe-56 in Fab
8062 induced the changes in the conformation of CDR-H2 that
were correlated in this study to the lack of biological activity of Fab
8062. Nevertheless, Fab 8069 has two-fold higher affinity for the
N-HR mimetic NCCG-gp41 than Fab 8066 (,7 versus ,15 nM;
[39]), a KD of 10-20 nM for binding to 5-Helix (unpublished data),
and weak neutralization activity, roughly comparable to that of the
parental Fab 3674 [39]. Modeling of the CDR-H2 of Fab 8069
based on that of the Fab 8062 complex shows that simple
replacement of Phe-56 by a Trp results in numerous short contacts
with residues of the Nc helix (Fig. 12B). Thus accommodation of a
Trp at position 56 requires some structural rearrangements to
occur within the gp41 bundle. However, since plasticity of the
isolated N-HR trimer is likely to be greater than that of 5-Helix,
such rearrangement could be readily achieved. While affecting the
overall structure of a trimer, modeling suggests that, when bound,
Trp-56 makes multiple tight contacts with an N-HR helix. This is
reflected in the high affinity of Fab 8069 for the N-HR mimetic
NCCG-gp41 [39]. However, shifts in the N-HR helices required to
accommodate Trp-56 may prevent binding of more than one
antibody molecule. This is in agreement with neutralization
studies carried out in the presence of NCCG-gp41 which failed to
demonstrate maximum antagonism at a molar ratio of Fab 8069 to
NCCG-gp41 of 3:1 (unpublished data), in contrast to the results
with Fab 8066 [39] and even Fab 8064 (unpublished data) where
maximum antagonism was observed at a 3:1 molar ratio.
Based on the HIV-1/SIVcpz protein alignment from the 2009
Los Alamos Sequence Compendium [44], the N-HR epitope
recognized by the two Fabs and the D5 antibody is highly
conserved. The same or a closely overlapping epitope is also
recognized by there other neutralizing antibodies directed against
the N-HR trimer of gp41, namely DN9 and 8K8 [38]and HK20
[33]. Using the native gp160 numbering, the epitope comprises
residues 560, 563–565, 567, 568, 570–577 and 579 of the N-HR
(For the corresponding numbers of the residues in 5-helix in the
structures of the complex, see Figure S1 in Supporting
Information S1). Of these 15 residues, eight are absolutely
conserved, and all substitutions involving the remaining seven
residues are highly conservative (E560N/Q, Q563R, H564Q/R,
L565M, I573V, Q577R and R579Q). Ten N-HR residues (656,
570–577 and 579) interact with the CDR-H2, of which seven are
absolutely conserved. In contrast, much more variability is seen for
the seven C-HR residues within the epitope: only one residue is
absolutely conserved (E647), three are subject to conservative
substitutions (D632E, H643Y and I646L), and three (residues 629,
636 and 640) are not conserved at all. Only two C-HR residues,
both of which are subject to conservative substitutions, interact
with the heavy chain (CDR-H3). None of the C-HR residues that
contact CDR-L1 are conserved, and two out of three that contact
CDR-L2 are also not conserved. The two residues (E647 and
H643Y) contacting CDR-L2, however, are highly preserved. Thus,
one can conclude that the broadly neutralizing properties of Fab
8066 largely originate from the conservation of the N-HR epitope
across different strains and clades of HIV-1.
The remarkable difference in the neutralization activities of
Fabs 8066 and 8062 [39], despite relatively small differences in the
interactions with the antigen when compared with the D5
complex, would also suggest that adapting a productive confor-
mation while binding to the pre-hairpin intermediate of gp41 is
accompanied by structural rearrangements in the CDR-H2
region. It seems likely that the presence of two Phe residues at
positions 54 and 56 of the CDR-H2 of Fab 8062 may result in a
reduction in conformational plasticity of the CDR-H2 loop of Fab
8062 relative to that of Fab 8066, which results in the two Fabs
adopting distinct CDR-H2 conformations upon binding 5-Helix.
In both complexes every residue of the CDR-H2 loop is involved
in interactions with 5-Helix, but topologically they are located very
differently in relation to the body of the bundle (Figs. 2C, 5B and
5C). In particular, the CDR-H2 of Fab 8066 is buried in the body
of the bundle, whereas in the case of Fab 8062 it is barely touching
its surface (Figs. 5B, C). This difference also impacts the local
conformation of 5-Helix, reflected by small but significant
backbone atomic displacements in the region contacting the
CDR-H2, as well as in immediately adjacent areas. The structural
differences involving interactions of CDR-H2 with 5-Helix in the
Fab 8066 and 8062 complexes are likely to perturb the lifetimes of
the two complexes (as reflected in dissociation rate constants and
hence affinity since the association rate constants are similar for
the two complexes; unpublished data). Since the antibodies take
the place of the Cc helix needed for completion of the structure of
the 6-HB conformation of gp41 (Fig. 9), the lifetime of the
complex will correlate with the ability of the antibody to prevent
creation of a proper 6-HB needed for viral entry.
Figure 11. Superimposed models of the complexes of the trimer of N-HR helices of gp41 with three Fab molecules, built by
sequentially superimposing single helices. (A) Overall view of the model shown in a cartoon representation. The modeled structures of the
complexes are colored cyan for Fab 8066, yellow for Fab 8062, and magenta for D5. (B) Expansion of the area of steric clashes between neighboring
Fab molecules. (C) Detailed view of the clashes between the CDR-H2 of one Fab and the CDR-L3 of another. (D) Detailed view of the steric clashes
between the residues from the loop 71–77 of one Fab and the CDR-L1 of another. (E) Enlarged view of the trimer of N-HR helices in the models. (F)
Stereoview corresponding to panel (E). (G), (H) and (I) Stereoviews of the superimposed trimers in crystal structures (light shades) and the models
(dark shades) for Fab 8066, Fab 8062, and D5, respectively.
doi:10.1371/journal.ppat.1001182.g011
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CDR-H2 of Fab 8066 and 8062 with 5-Helix also result in smaller
propagated structural changes throughout the complex, which are
likely to further contribute to the different binding affinities with
5-Helix. For example, there are a few additional interactions
involving CDR-H3 (Fig. 6), CDR-L1 (Fig. 7A), CRD-L2 (Fig. 8),
and CDR-L3 (Fig. 8) in the Fab 8066 complex compared to the
Fab 8062 complex. Further, some of the interactions that are
present in both complexes are stronger (i.e. shorter intermolecular
contacts) in the Fab 8066 complex. Indeed, the gap volume index
Figure 12. Modeled binding of the CDR-H29s of Fabs 8065 and 8069 to 5-Helix. Helices of the N-HR trimer (cyan) are shown as a cartoon,
with selected residues in stick representation. CDR-H29s with selected residues shown as sticks are colored magenta. Short contacts are indicated by
black dashed lines. (A) Model of the CDR-H2 of Fab 8065, with Trp-53 and His-54 shown in stick representation. The second rotamer of Trp-53 is
shown in light brown, CDR-H1 and CDR-L1 with selected residues in stick are shown in pink and green, respectively. (B) A model of the CDR-H2 of Fab
8069, with Trp-56 shown in stick representation.
doi:10.1371/journal.ppat.1001182.g012
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significantly smaller in the Fab 8066 complex (2.3 A ˚) than in the
Fab 8062 complex (2.6 A ˚).
Although Fabs 8066 and 8062 are both able to bind to the
exposed N-HR trimer with similarly high affinity [39], their ability
to bind to the 5-Helix construct differs by about 2 orders of
magnitude, and that difference is reflected in their neutralization
activity (Table 1). This observation leads us to two conclusions.
First, the interactions of the Ca helix of 5-Helix with the CDR-H3
(Fig. 6), CDR-L2 (Fig. 8) and CDR-L3 (Fig. 8) loops may
modulate the affinity of Fabs 8066 and 8062. Second, the assay
(involving a solution equilibrium titration in conjunction with an
electrochemiluminescence-based affinity measurement) used to
determine KD values for the binding of Fabs to the N-HR trimer
mimetic NCCG-gp41 reported by Gustchina et al. [39] reflect the
binding of only a single Fab to NCCG-gp41, and hence do not
report on any possible negative cooperativity arising from steric
clash between neighboring Fabs bound to the N-HR trimer
(cf. Fig. 11).
A key feature of fusion inhibitors that target the N-HR trimer,
including presumably antibodies directed against the N-HR
trimer, is that deactivation of gp41 in vivo is a slow reversible
process that is dependent on chemokine receptor binding to Env,
and that the exposed N-HR trimer remains accessible to inhibitors
until the final conformational changes in gp41 that lead to the
formation of the 6-HB have taken place [31]. This suggests that
inhibition of fusion will be most effective when two or more Fabs
are bound to the exposed N-HR trimer of the pre-hairpin
intermediate of gp41. Since multiple Fabs/antibodies bound to the
N-HR trimer are unlikely to dissociate simultaneously, the
probability that at least one antibody is bound to the N-HR
trimer at all times will be increased. Our modeling suggests that
three molecules of the most potent neutralizing Fab in our series,
Fab 8066, can readily bind to the N-HR trimer without any steric
clashes between adjacent Fab molecules (Figs. 10 and 11). In
contrast, as a consequence of the different mode of binding of the
CDR-H2 to the hydrophobic pocket on the surface of the N-HR
trimer, binding of three molecules of Fab 8062 to the N-HR trimer
may result in steric clash between adjacent Fab molecules
involving the CDR-H2, CDR-L1, CDR-L3 loops and loop 71–
78 (Fig. 11). It seems likely in the light of the current structural
data, modeling results and neutralization properties of our Fab
series [39], that neutralization is dependent not only on tight
binding of a single Fab to the N-HR trimer but also on the ability
to bind multiple Fabs to a single N-HR trimer at a preliminary
step of the fusion process.
Materials and Methods
Expression and purification of 5-Helix and Fabs 8066 and
8062
The plasmid construct to express 5-Helix fused to a C-terminal
His-tag was generously provided by Michael Root (Thomas
Jefferson University). A stop codon was engineered preceding the
His-tag using the Quik-Change mutagenesis protocol (Stratagene,
La Jolla, CA) to express a tag-less version of 5-Helix. 5-Helix was
expressed in E. coli, purified from the insoluble fraction under
denaturing conditions on a Superdex-200 column, and then
subjected to reverse-phase HPLC. The protein was dialyzed
against 50 mM sodium formate, pH 3, concentrated to ,10 mg/
ml and stored at 4uC.
Fabs 8066 and 8062 were initially expressed and purified as
described previously. Further purification was carried out by size-
exclusion chromatography on a Superose-12 column (16660 cm,
GE HealthCare) equilibrated in 10 mM Tris-HCl, pH 7.5,
150 mM NaCl. Peak fractions were pooled and concentrated to
,2 mg/ml and stored frozen. The D5 monoclonal antibody in
IgG and Fab formats was generously provided by Joseph Joyce
(Merck Research Laboratories).
Liquid chromatography-mass spectrometry/mass spectrometry
analysis [45] of endoprotease (trypsin, Lys-C, Glu-C, chymotryp-
sin) digested Fabs either as liquid samples [46] or after separation
by SDS/PAGE [47] was used to provide partial sequence
information of regions of the engineered Fabs prior to obtaining
the full sequences from AbD Serotec.
Assessment of the Fab/5-Helix complexes by SMR
Size exclusion chromatography with detection by Multiangle
light scattering (DAWN EOS, Wyatt Technology Inc., Santa
Barbara, CA) and Refractive index (OPTILAB DSP, Wyatt
Technology) (SMR) was used for mass analysis of 5-Helix in
complex with Fab 8066 and to optimize conditions for the large-
scale preparation of complexes for crystallization. 5-Helix (103 mg)
and Fab 8066 (106 mg) before and after mixing with each other
(,50 mg each giving a molar ratio of 1:2 Fab 8066 to 5-Helix) in a
final volume of 150 ml were loaded on Superdex-75 column
(1630 cm) equilibrated in 1x PBS at a flow rate of 0.5 ml at room
temperature. Molecular masses were calculated using the Astra
software provided with the instrument.
Preparation of large-scale antigen-antibody complexes
Preparation of the Fab 8066/5-Helix complexes for crystalliza-
tion was carried out by slowly mixing 64 ml of 5-Helix (575 mg
corresponding to a 1.5-fold molar excess over Fab) with 1.5 ml of
Fab (, 0.8 mg) solution kept in 10 mM Tris-HCl, pH 7.5 and
150 mM NaCl and separating the complex on a Superose-12
column (16660 cm) in the same buffer. Because of the lower
affinity of Fab 8062 for 5-Helix, a 3-4 fold higher protein
concentration of the Fab 8062/5-Helix complex was maintained
prior to subjecting the complex for fractionation on the column.
The complexes were concentrated to a final concentration of
,10 mg/ml and stored at 4uC.
Isothermal Titration Calorimetry (ITC)
ITC measurements were performed using an ITC200 titration
calorimeter (Microcal Inc.) at 28uC. The stock solution (,10 mg/
ml) of 5-Helix in 50 mM sodium formate, pH 3, was diluted to
about 0.5 mg/ml in 25 mM Tris-HCl, pH 7.5, 150 mM NaCl,
dialyzed against 10 mM Tris, pH 7.5, 150 mM NaCl and
concentrated to ,5 mg/ml. Antibody solutions (5–15 mM) in
10 mM Tris, pH 7.5, 150 mM NaCl kept in the calorimetric cell
were titrated against 10 and 20 fold higher concentration of
5-Helix for monovalent Fabs 8062, 8066 and D5, respectively.
The data were analyzed using the Origin software provided with
the instrument.
HIV-1 neutralization assay
The cell lines and molecular clones employed were identical to
those described in our previous publication [39]. Preparation of
Env-pseudotyped HIV-1 and Env-pseudotyped HIV neutraliza-
tion assays (employing TZM-b1 indicator cells that constitutively
express CD4, CCR4 and CXCR4) were carried out exactly as
described previously [39].
Crystallographic procedures
Crystallization of the Fab 8066/5-Helix and Fab 8062/5-Helix
complexes was carried out by the hanging drop, vapor diffusion
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7 mg/ml in 10 mM Tris buffer at pH 8.0, also containing 0.15 M
NaCl. The reservoir solution contained 1.2 M dibasic ammonium
phosphate in 0.1 M HEPES buffer at pH 8.0. Each drop
contained 2 ml of protein samples and 2 ml of reservoir solution.
The crystals grew to the maximum size of ,0.2 mm in 4 to 5 days.
The Fab 8062/5-Helix complex was treated in a similar way, with
the exception that the well solution contained 14% polyethylene
glycol 10K, 0.1 M ammonium sulfate, and 5% ethylene glycol.
Diffraction data for both complexes were collected using
synchrotron radiation at the SER-CAT ID-22 beamline at the
APS, Argonne National Laboratory, from one crystal each. The
resolution of the data for the Fab 8066/5-Helix complex and Fab
8062/5-Helix complex was 2.05 and 2.5 A ˚, respectively. The
structure of the Fab 8066/5-Helix complex was solved by
molecular replacement with the program PHASER [48], using
the coordinates of the D5/5-Helix complex ([41] PDB ID 2CMR)
as the search model. The structure was completed through a
number of cycles of refinement with REFMAC5 [49] and
rebuilding with COOT [50]. The refined structure of the Fab
8066/5-Helix complex was used as the search model to solve the
structure of the Fab 8062/5-Helix complex, with similar
procedures used for subsequent refinement and model building.
The statistics for data collection and structure refinement are listed
in Table 2. The coordinates and structure factors for the Fab
8066/5-Helix and Fab 8062/5-Helix complexes have been
deposited in the Protein Data Bank with IDs 3MA9 and 3MAC,
respectively.
Supporting Information
Supporting Information S1 Figures and Tables providing a
reference for the residue numbering in 5-helix (Figure S1), a
detailed list of antigen-antibody contacts (Table S1), and a
comparison of CDR-H2 sequences of neutralizing and non-
neutralizing antibodies (Table S2).
Found at: doi:10.1371/journal.ppat.1001182.s001 (0.11 MB PDF)
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